The European Medicines Agency (EMA) has released the beta version of the Product Management Service (PMS) Public Application Programming Interface (API), marking an important milestone in the development of the PMS.
 
Date: 12/06/2026
 

The European Medicines Agency (EMA) has released the beta version of the Product Management Service (PMS) Public Application Programming Interface (API), marking an important milestone in the development of the PMS.

For the first time, selected public medicinal product data held in PMS is being made available externally in a structured, machine-readable and reusable format through an application programming interface (API).

 

What is new?

The existing public Product User Interface already allows users to search for and view public product data. The new beta Public API goes a step further by enabling programmatic access to selected public data, making it easier for external users and systems to:

  • retrieve product data automatically;

  • integrate it into digital tools and services;

  • reuse it for analysis and interoperability purposes.

     

What data is being made available?

The beta release includes selected public data for human medicines authorised in the EU, in line with the agreed PMS scope and public data classification approach.

 

Why is this important?

The release supports:

  • increased transparency of EU medicinal product data;

  • wider reuse of structured product data;

  • improved interoperability;

  • future public-facing and cross-border use cases.

     

Why is it a beta release?

The beta version is a controlled first step. It allows users to begin exploring and using the API while EMA continues to strengthen the service over time.

In parallel, EMA will continue a structured programme of work during the second half of 2026 focused on:

  • data quality reporting to monitor error types and frequency;

  • technical enhancements to resolve system bugs and root causes of data quality issues;

  • data correction activities to improve the reliability of the published data.

The decision to move from beta to full public release will depend on meeting defined success criteria, including key data quality metrics supporting Pharmacovigilance use cases.

 

Access and support

The beta Public API is subject to EMA’s API Terms and Conditions of use. Further information, supporting materials and updates are available here:

Substance and product data management services | European Medicines Agency (EMA)

 

Upcoming dedicated webinar

A dedicated public webinar will also take place on 13 July 2026, providing a detailed overview of access and data read through the PMS public API, featuring a live demonstration and an open Q&A session to address participants’ questions. Register here to the WebEx session: event page link.